BIO Stock Might Rise Following the Offer to Acquire Stilla

Bio-Rad Laboratories, Inc. BIO recently entered into a binding agreement to purchase all equity interests in Stilla Technologies ("Stilla"). Stilla’s next-generation digital PCR solutions complement Bio-Rad’s digital PCR portfolio. The acquisition should further expand Bio-Rad’s business into applied research and clinical diagnostics, where customers expect a higher degree of automation and throughput capabilities.The acquisition is subject to consultation with relevant employee representatives, regulatory approvals and other customary closing conditions. The acquisition is expected to be closed by the end of the third quarter of 2025. BIO Stock Likely Trend Following the NewsSince the announcement, BIO stock has lost 9.5% to $277.16 last Friday.The company has been gaining synergies from its digital PCR platform’s increased penetration in advanced clinical diagnostic applications, both directly and through various partnerships. In 2024, Bio-Rad was involved in various collaborations, including an additional equity investment in OncoCyte Corporation and association with Allegheny Health Network. Accordingly, we expect the latest acquisition offer to bolster investor confidence and bring back the upward momentum in BIO's share price in the coming days.Bio-Rad has a market capitalization of $7.94 billion. The Zacks Consensus Estimate for fiscal 2025 earnings indicates a 12.2% year-over-year increase on a 3.4% revenue improvement. Importance of Bio-Rad’s Acquisition of StillaStilla develops and markets next-generation digital PCR instruments, consumables and assays. Its Nio family of all-in-one digital PCR systems aids the development of a wide range of genetic tests and molecular assays across multiple applications, including liquid biopsy for oncology diagnostics, cell and gene therapy, organ transplant testing, infectious diseases, and food and environmental testing.The Stilla platform would allow Bio-Rad to serve the full range of digital PCR applications and help meet the evolving needs of customers in genomics research and applied science. In lieu of this, Bio-Rad plans to launch its QX Continuum system.  Image Source: Zacks Investment ResearchIndustry Prospects Favor Bio-RadPer a report by Fortune Market Insights, the global digital PCR market was valued at $584.5 million in 2023 and is projected to grow to $3.68 billion by 2032, exhibiting a CAGR of 22.9% during the period. The rise in prevalence of infectious diseases, cancer, and genetic disorders, technological advancements, and the growing adoption of the technology by laboratories are some of the key factors expected to drive the market growth.BIO’ Price PerformanceIn the past year, BIO’s shares have declined 18.6% against the industry’s 13.9% growth.BIO’ Zacks Rank and Other Key PicksThe company currently carries a Zacks Rank #2 (Buy).Some other top-ranked stocks in the broader medical space are Veracyte VCYT, ResMed RMD and Omnicell OMCL.Veracyte, carrying a Zacks Rank #1 (Strong Buy) at present, has an estimated earnings growth rate of 65.8% for 2025. You can see the complete list of today’s Zacks #1 Rank stocks here.VCYT’s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 520.58%. Veracyte’s shares have risen 49.2% in the past year compared with the industry’s 5.5% growth.ResMed, carrying a Zacks Rank #2 at present, has an estimated growth rate of 21.1% for 2025. RMD’s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 6.41%. Its shares have risen 34.1% compared with the industry’s 7.7% growth in the past year. Omnicell, carrying a Zacks Rank #2 at present, has an estimated earnings growth rate of 72.7% for fourth-quarter 2024. Its earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 121.74%. OMCL’s shares have risen 26.4% against the industry’s 15.7% decline in the past year. Only $1 to See All Zacks' Buys and SellsWe're not kidding.Several years ago, we shocked our members by offering them 30-day access to all our picks for the total sum of only $1. No obligation to spend another cent.Thousands have taken advantage of this opportunity. Thousands did not - they thought there must be a catch. Yes, we do have a reason. We want you to get acquainted with our portfolio services like Surprise Trader, Stocks Under $10, Technology Innovators,and more, that closed 256 positions with double- and triple-digit gains in 2024 alone.See Stocks Now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Omnicell, Inc. (OMCL): Free Stock Analysis Report ResMed Inc. (RMD): Free Stock Analysis Report Bio-Rad Laboratories, Inc. (BIO): Free Stock Analysis Report Veracyte, Inc. (VCYT): Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks